Wearable sensor patch to spot early worsening in cardiogenic shock
Tests a wearable sensor patch in adults with cardiogenic shock.
Key facts
- Who runs it
- NIRSense Inc.
- Where
- Weston, United StatesSee the site
- Trial code
- Registry title
- Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 17 Jun 2025
- Expected to end
- Aug 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- NIRSense Tissue Oximetry Sensor System
- Record updated
- 17 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the cardiac intensive care unit with a heart attack or worsening heart failure who are in SCAI shock stage B, C, or D. They wear a sensor patch for about 24 to 72 hours.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Worsening heart failure with symptoms, or a heart attack with coronary angiography; admitted to intensive care in SCAI shock stage B, C, or D.
Main reasons for not taking part
- Known severe allergy to medical adhesive or tape (self-reported)
- Taking part in another drug or device study that would interfere with this one
- Weight of 40 kg (88 lb) or less
- The investigator thinks the person is not an appropriate candidate
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Acutely decompensated symptomatic heart failure (HF) documented by: (a) symptoms of HF requiring current treatment; (b) Society for Cardiovascular Angiography and Interventions (SCAI) stage B, C, or D; and (c) hospital admission with HF as the primary or secondary diagnosis; OR acute myocardial infarction (MI) patient undergoing coronary angiography
- Admitted to the intensive care unit and currently in SCAI stage B, C, or D
- Age 18 years or older
- Weight greater than 40 kg
Who cannot take part
- Prior known severe allergy to medical-grade adhesive or tape (self-reported)
- Currently participating in an investigational drug or device study that would interfere with the conduct or results of this study. Trials requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational
- The investigator believes the participant is not an appropriate candidate for the study
Where in United States
- Cleveland Clinic Florida, Weston HospitalWeston, United StatesContact: David A. Baran, MDTaking people
About the trial
What the trial wants to find out
This is a prospective, single-center, observational pilot study of the investigational NIRSense Tissue Oximetry Sensor System (Envello Core), a noninvasive wearable sensor patch that uses near-infrared spectroscopy (NIRS) and photoplethysmography (PPG), combined with an electrocardiography/impedance cardiography (ECG/ICG) sensor, to continuously monitor tissue oxygen saturation (StO2), peripheral oxygen saturation (SpO2), pulse rate, respiratory rate, stroke volume, and related metrics. Up to 20 adults admitted to the Cleveland Clinic Florida cardiac intensive care unit with acute myocardial infarction or acute decompensated heart failure and in Society for Cardiovascular Angiography and Interventions (SCAI) shock stage B, C, or D will wear the sensors on the sternum, forearm, and other locations for approximately 24 to 72 hours during standard care. Sensor data will be compared with standard-of-care hemodynamic and laboratory measurements and with the patient's clinical course to evaluate the feasibility of the device, the correlation of its measurements with established clinical parameters, and its potential to detect deterioration in SCAI shock stage earlier. No treatment decisions are made based on the study device.
The 2 groups in the trial
- Acute myocardial infarction
Patients with acute myocardial infarction, with or without shock (SCAI stage B to D), admitted for coronary angiography and subsequent interventions. Enrolled at the time of consent for coronary angiography.
Treatment: NIRSense Tissue Oximetry Sensor System
- Acute decompensated heart failure
Patients with acute decompensated heart failure (SCAI stage B to D) admitted for pulmonary artery catheter insertion and subsequent interventions. Consented before or after catheterization.
Treatment: NIRSense Tissue Oximetry Sensor System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Evaluation of Using NIRSense Sensor Patch to Measure Microvascular Perfusion Responses and Predict Decompensation in Cardiogenic Shock Patients
- Plain-language title
- Wearable sensor patch to spot early worsening in cardiogenic shockGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 September 2026